Key result
Metformin reduces plasma activin A versus pioglitazone in men with type 2 diabetes.
Why the study?
Activin A released from epicardial adipose tissue has been linked to contractile dysfunction and insulin resistance in cardiomyocytes, but its role in clinical diabetic cardiomyopathy is unclear.
Does treatment with pioglitazone versus metformin alter circulating activin A levels and its association with myocardial glucose metabolism and left ventricular remodeling in men with uncomplicated type 2 diabetes?
Comparison
Pioglitazone versus metformin for 24 weeks
Design
Randomized double-blind active comparator intervention study
Follow-up
24 weeks
Authors
Loading...
Metformin lowers activin A more than pioglitazone in uncomplicated T2D; extends activin A link to early diabetic cardiomyopathy.
RCT (n=92)
Double-blind
Randomized
Yes
Does treatment with pioglitazone versus metformin alter circulating activin A levels and its association with myocardial glucose metabolism and left ventricular remodeling in men with uncomplicated type 2 diabetes?
Absolute Event Rate: 302% vs 261%
p-value: p=<0.001
Circulating activin A levels are associated with impaired myocardial glucose metabolism and left ventricular remodeling in men with uncomplicated type 2 diabetes, suggesting a potential role in early diabetic cardiomyopathy.
Chen et al. (2013) conducted an RCT in Uncomplicated type 2 diabetes (n=92). Pioglitazone vs. Metformin was evaluated on Change in plasma activin A levels (p=<0.001). Metformin treatment significantly decreased plasma activin A levels compared to pioglitazone in men with uncomplicated type 2 diabetes, while baseline activin A levels correlated with impaired myocardial glucose metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: